Doehn C, Böhmer T, Sommerauer M, Kausch I, Jocham D
Klinik und Poliklinik für Urologie, Universitätsklinikum Schleswig-Holstein (UKSH), Campus Lübeck.
Aktuelle Urol. 2005 Sep;36(5):407-16. doi: 10.1055/s-2005-915571.
Vaccine therapy of prostate cancer has been increasingly studied in trials over the past few years. The different vaccine techniques are quite variable and are predominantly used in patients with advanced hormone-refractory prostate cancer. In this review, vaccine techniques using tumor cells, dendritic cells or poxvirus are analyzed. For theses approaches phase-III trials are being planned, have been initiated or are already completed. Many trials demonstrate the efficacy with regard to endpoints such as stimulation of the immune system and/or biochemical response and/or clinical response. Recently, one vaccine approach using autologous dendritic cells demonstrated a statistically significant prolongation of overall survival compared to placebo in patients with hormone-refractory prostate cancer. Side effects of vaccination are generally mild. At present, there are trials are being planned or are already ongoing that combine vaccine with other treatment strategies or enroll patients with earlier disease stages.
在过去几年中，前列腺癌的疫苗治疗在试验中得到了越来越多的研究。不同的疫苗技术差异很大，主要用于晚期激素难治性前列腺癌患者。在本综述中，分析了使用肿瘤细胞、树突状细胞或痘病毒的疫苗技术。对于这些方法，正在计划、已经启动或已经完成III期试验。许多试验证明了在诸如刺激免疫系统和/或生化反应和/或临床反应等终点方面的疗效。最近，一种使用自体树突状细胞的疫苗方法显示，与安慰剂相比，激素难治性前列腺癌患者的总生存期有统计学意义的延长。疫苗接种的副作用通常较轻。目前，正在计划或已经在进行将疫苗与其他治疗策略相结合或纳入疾病分期较早患者的试验。
